Piramal Pharma posts robust Q2 growth, expands Lexington facility to meet demand
Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has reported strong growth for the second quarter (Q2) and first half (H1) of the fiscal year 2024-2025. The company’s consolidated revenue for Q2 rose by 17% year-on-year (YoY) to ₹2,242 crore, supported by significant demand in its contract development and manufacturing organization (CDMO) business. Piramal also […]